Industry News

Aclaris Therapeutics, Inc, a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for a Phase 1a/1b clinical trial of ATI-052, a potential best-in-class bispecific anti-TSLP/IL-4R monoclonal antibody.

Novo Nordisk to stop selling its top brand Human Mixtard from India which is country's top selling insulin alone Rs. 800 Crore. Human Mixtard comes under DPCO and the company is reported to come up with new products in India.

Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients.

In people with this disease, small fibres of TTR protein clump together to make deposits called amyloid. Amyloid can build up around or within the nerves, heart and other organs, stopping them from working properly. Eplontersen is specifically indicated for use when the disease is causing polyneuropathy, which is damage to multiple nerves outside of the brain and central nervous system, resulting in pain, discomfort, progressive weakness and loss of sensation in the legs and arms, and mobility difficulties.

Lupin Healthcare Limited, the wholly owned subsidiary of global pharma major Lupin Limited announced today the acquisition of Renascience Pharma Limited , a UK-based pharmaceutical company and sole supplier of 4 specialty products targeting unmet medical needs in the UK.

Discovered by GSK scientists, Blujepa is a first-in-class oral antibiotic with a novel mechanism of action that is part of GSK’s infectious diseases portfolio.

Novartis announced that oral Fabhalta iptacopan has received U.S. Food and Drug Administration (FDA) approval for the treatment of adults with C3 glomerulopathy (C3G), to reduce proteinuria, making it the first and only treatment approved for this condition.

Zydus Life sciences Limited has received final approval from the United States Food and Drug Administration USFDA to manufacture Apalutamide Tablets, 60 mg.